CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 62 enrolled
Drug / intervention
pembrolizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02733159
NCT02733159Phase 2Completed
CompareCT.gov

A Phase II Trial of Pembrolizumab in Patients With Non-small Cell Lung Cancer and a Performance Status of 2

University of Birmingham·interventional·Posted Apr 11, 2016·Updated Feb 10, 2025

In Brief

A Phase 2 clinical trial evaluating pembrolizumab for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 62 participants across 10 sites.

Detailed Summary

This study is to determine that pembrolizumab is safe and tolerable at the selected dose for the treatment of Non-Small Cell Lung Cancer (NSCLC) in patients with a performance status of 2. All patients will receive pembrolizumab.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesUnited Kingdom
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 11, 2016
Enrollment StartJan 4, 2017
Primary CompletionFeb 7, 2023
Study CompletionFeb 5, 2024
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 10.2 years ago

Interventions

pembrolizumabdrug

anti PD-1